Placental biglycan expression is decreased in human idiopathic Fetal growth restriction

Placenta

Volumn 31, Issue 8, 2010, Pages 712-717

  Murthi, P ^a,b   Faisal, F A ^a,b   Rajaraman, G ^a,b   Stevenson, J ^a,b   Ignjatovic, V ^b,c   Monagle, P T ^b,c   Brennecke, S P ^a,b   Said, J M ^a,b  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Dermatan sulphate; Fetal growth restriction; Gene expression; Placenta; Proteoglycans

Indexed keywords

BIGLYCAN; MESSENGER RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTRAUTERINE GROWTH RETARDATION; PLACENTA; PREGNANCY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

EID: 77955984317     PISSN: 01434004     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.placenta.2010.05.009     Document Type: Article

References (39)

1. Illanes and Soothill. Management of fetal growth restriction. Semin Fetal Neonatal Med 2004;9(5):395-401.
2. Godfrey KM, Barker DJ. Fetal nutrition and adult disease. Am J Clin Nutr 2000;71(Suppl. 5):1344S-52S.
3. Steffensen FH, Sorensen HT, Gillman MW, Rothman KJ, Sabroe S, Fischer P, et al. Low birth weight and preterm delivery as risk factors for asthma and atopic dermatitis in young adult males. Epidemiology 2000;11(2):185-8.
4. Rosso IM, Cannon TD, Huttunen T, Huttunen MO, Lonnqvist J, Gasperoni TL. Obstetric risk factors for early-onset schizophrenia in a Finnish birth cohort. Am J Psychiatry 2000;157(5):801-7.
5. Gale CR, Martyn CN. Birth weight and later risk of depression in a national birth cohort. Br J Psychiatry 2004;184:28-33.
6. Frisk V, Amsel R, Whyte HE. The importance of head growth patterns in predicting the cognitive abilities and literacy skills of small-forgestational- age children. Dev Neuropsychol 2002;22(3):565-93.
7. Brodsky D, Christou H. Current concepts in intrauterine growth restriction. J Intensive Care Med 2004;19(6):307.
8. Chang TC, Robson SC, Spencer JA, Gallivan S. Identification of fetal growth retardation: comparison of Doppler waveform indices and serial ultrasound measurements of abdominal circumference and fetal weight. Obstet Gynecol 1993;82(2):230-6.
9. Gagnon R. Placental insufficiency and its consequences. Eur J Obstet Gynecol Reprod Biol 2003;110(Suppl. 1):S99-107.
10. Kingdom J, Huppertz B, Seaward G, Kaufmann P. Development of the placental villous tree and its consequences for fetal growth. Eur J Obstet Gynecol Reprod Biol 2000;92(1):35-43.
11. Salafia CM, Silberman L, Herrera NE, Mahoney MJ. Placental pathology at term associated with elevated midtrimester maternal serum alpha-fetoprotein concentration. Am J Obstet Gynecol 1988;158(5):1064-6.
12. Sugimura M, Ohashi R, Kobayashi T, Kanayama N. Intraplacental coagulation in intrauterine growth restriction: cause or result? Semin Thromb Hemost 2001;27(2):107-14.
13. Ishiguro K, Kadomatsu K, Kojima T, Muramatsu H, Nakamura E, Ito M, et al. Syndecan-4 deficiency impairs the fetal vessels in the placental labyrinth. Dev Dyn 2000;19(4):539-44.
14. Brenner B. Haemostatic changes in pregnancy. Thromb Res 2004;114(5-6):409-14.
15. Bremme KA. Haemostatic changes in pregnancy. Best Pract Res Clin Haematol 2003;16(2):153-68.
16. O'Riordan MN, Higgins JR. Haemostasis in normal and abnormal pregnancy. Best Pract Res Clin Obstet Gynaecol 2003;17(3):385-96.
17. Delorme MA, Burrows RF, Ofosu FA, Andrew M. Thrombin regulationinmother and fetus during pregnancy. Semin Thromb Hemost 1992;18(1):81-90.
18. Pinto S, Abbate R, Rostagno C, Bruni V, Rosati D, Neri Serneri GG, et al. Increased thrombin generation in normal pregnancy. Acta Eur Fertil 1988;19(5):263-7.
19. Andrew M, Mitchell L, Berry L, Paes B, Delorme M, Ofosu F. An anticoagulant dermatan sulfate proteoglycan circulates in the pregnant woman and her fetus. J Clin Invest 1992;89(1):321-6.
20. Delorme MA, Xu L, Berry L, Mitchell L, Andrew M. Anticoagulant dermatan sulfate proteoglycan (decorin) in the term human placenta. Thromb Res 1998;90(4):147-53.
21. Giri TK, Tollefsen DM. Placental dermatan sulfate: isolation, anticoagulant activity, and association with heparin cofactor II. Blood 2006;107(7):2753-8.
22. Wasserman L, Shlesinger H, Abramovici A, Goldman JA, Allalouf D. Glycosaminoglycan patterns in diabetic and toxemic term placentas. Am J Obstet Gynecol 1980;138(7 Pt 1):769-73.
23. Swan B, Murthi P, Rajaraman G, Pathirage NA, Said JM, Ignjatovic V, et al. Decorin expression is decreased in human idiopathic fetal growth restriction. Reproduction Fertility and Develeopment 2010;22:949-55.
24. Guaran RL, Wein P, Sheedy M, Walstab J, Beischer NA. Update of growth percentiles for infants born in an Australian population. Aust N Z J Obstet Gynaecol 1994;34(1):39-50.
25. Murthi P, Doherty V, Said J, Donath S, Brennecke SP, Kalionis B. Homeobox gene HLX1 expression is decreased in idiopathic human fetal growth restriction. Am J Pathol 2006;168:511-8.
26. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using realtime quantitative PCR and the 2-ΔΔCT method. Methods 2001;25(4):402-8.
27. Chen CP, Chang SC, Vivian Yang WC. Highglucosealters proteoglycan expression and the glycosaminoglycan compositioninplacentasofwomen with gestational diabetes mellitus and in cultured trophoblasts. Placenta 2006;28:97-106.
28. Gogiel T, Galewska Z, Jaworski S. Pre-eclampsia-associated alterations in Wharton's jelly proteoglycans. Acta Biochim Pol 2005;52(2):501-7.
29. Warda M, Zhang F, Radwan M, Zhang Z, Kim N, Kim YN, et al. Is human placenta proteoglycan remodeling involved in pre-eclampsia? Glycoconj J 2008;25(5):441-50.
30. San Martin S, Zorn TM. The small proteoglycan biglycan is associated with thick collagen fibrils in the mouse decidua. Cell Mol Biol 2003;49(4):673-8.
31. Douglas T, Heinemann S, Bierbaum S, Scharnweber D, Worch H. Fibrillogenesis of collagen types I, II, and III with small leucine-rich proteoglycans decorin and biglycan. Biomacromolecules 2006;7(8):2388-93.
32. Corsi A, Xu T, Chen XD, Boyde A, Liang J, Mankani M, et al. Phenotypic effects of biglycan deficiency are linked to collagen fibril abnormalities, are synergized by decorin deficiency, and mimic Ehlers-Danlos-like changes in bone and other connective tissues. J Bone Miner Res 2002;17(7):1180-9.
33. Reinboth B, Thomas J, Hanssen E, Gibson MA. Beta ig-h3 interacts directly with biglycan and decorin, promotes collagen VI aggregation, and participates in ternary complexing with these macromolecules. J Biol Chem 2006;281(12):7816-24.
34. Little PJ, Osman N, O'Brien KD. Hyperelongated biglycan: the surreptitious initiator of atherosclerosis. Curr Opin Lipidol 2008;19(5):448-54.
35. Gogiel T, Galewska Z, Romanowicz L, Jaworski S, Bankowski E. Pre-eclampsiaassociated alterations in decorin, biglycan and versican of the umbilical cord vein wall. Eur J Obstet Gynecol Reprod Biol 2007;134(1):51-6.
36. He L, Giri TK, Vicente CP, Tollefsen DM. Vascular dermatan sulfate regulates the antithrombotic activity of heparin cofactor II. Blood 2008;111(8):4118-25.
37. Klaritsch P, Haeusler M, Karpf E, Schlembach D, Lang U. Spontaneous intrauterine umbilical artery thrombosis leading to severe fetal growth restriction. Placenta 2008;29(4):374-7.
38. Wilkins-Haug L, Quade B, Morton CC. Confined placental mosaicism as a risk factor among newborns with fetal growth restriction. Prenatal Diagn 2006;26(5):428-32.
39. Tovar AM, de Mattos DA, Stelling MP, Sarcinelli-Luz BS, Nazareth RA, Mourão PA. Dermatan sulfate is the predominant antithrombotic glycosaminoglycan in vessel walls: implications for a possible physiological function of heparin cofactor II. Biochim Biophys Acta 2005;1740(1):45-53.